RELMADA THERAPEUTICS, INC. Cash, Period Increase (Decrease)
RELMADA THERAPEUTICS, INC. (RLMD) reported Cash, Period Increase (Decrease) of -$11.12 million for the 9-month period ending 2016-03-31, per its 10-Q filed 2016-05-09.
Discontinued › Notes
us-gaap:CashPeriodIncreaseDecrease · last filed 2016-05-09
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for the quarter ending 2016-03-31 was -$3.78M.
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for the quarter ending 2015-12-31 was -$4.04M, a 200.24% decline year-over-year.
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for the quarter ending 2015-09-30 was -$3.30M, a 280.92% decline year-over-year.
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for the quarter ending 2015-06-30 was -$4.49M, a 119.42% decline year-over-year.
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for fiscal 2015 was -$3.09M.
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for fiscal 2013 was $1.75M.
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for fiscal 2013 was $6.34K.
- RELMADA THERAPEUTICS, INC. cash, period increase (decrease) for fiscal 2012 was $1.75M.
| Period end | Cash, Period Increase (Decrease) 3 month | Cash, Period Increase (Decrease) 6 month | Cash, Period Increase (Decrease) 9 month | Cash, Period Increase (Decrease) 12 month | Cash, Period Increase (Decrease) 21 month | Cash, Period Increase (Decrease) 24 month | Cash, Period Increase (Decrease) 27 month | Cash, Period Increase (Decrease) 30 month | Cash, Period Increase (Decrease) 33 month | Cash, Period Increase (Decrease) 115 month | Cash, Period Increase (Decrease) 118 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-03-31 | -$3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09 | -$7.82M derived: sum of 2 quarters · filed 2016-05-09 | -$11.12M 10-Q · filed 2016-05-09 | -$15.61M derived: sum of 4 quarters · filed 2016-05-09 | |||||||
| 2015-12-31 | -$4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05 | -$7.34M 10-Q · filed 2016-02-05 | -$11.83M derived: sum of 3 quarters · filed 2016-02-05 | -$16.29M derived: sum of 4 quarters · filed 2016-05-09 | |||||||
| 2015-09-30 | -$3.30M 10-Q · filed 2015-11-06 | -$7.79M derived: sum of 2 quarters · filed 2015-11-06 | -$12.25M derived: sum of 3 quarters · filed 2016-05-09 | -$8.23M derived: sum of 4 quarters · filed 2016-05-09 | |||||||
| 2015-06-30 | -$4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-11 | -$8.95M derived: sum of 2 quarters · filed 2016-05-09 | -$4.92M derived: sum of 3 quarters · filed 2016-05-09 | -$3.09M 10-K · filed 2015-09-11 | |||||||
| 2015-03-31 | -$4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09 | -$434.42K derived: sum of 2 quarters · filed 2016-05-09 | $1.39M 10-Q · filed 2016-05-09 | $24.50M derived: sum of 4 quarters · filed 2016-05-09 | |||||||
| 2014-12-31 | $4.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05 | $5.85M 10-Q · filed 2016-02-05 | $28.96M derived: sum of 3 quarters · filed 2016-02-05 | $27.90M derived: sum of 4 quarters · filed 2016-02-05 | |||||||
| 2014-09-30 | $1.83M 10-Q · filed 2015-11-06 | $24.93M derived: sum of 2 quarters · filed 2015-11-06 | $23.87M derived: sum of 3 quarters · filed 2015-11-06 | ||||||||
| 2014-06-30 | $23.11M derived: 10-K 6 month − 8-K 3 month · filed 2015-09-11 | $22.04M 10-K · filed 2015-09-11 | |||||||||
| 2014-03-31 | -$1.06M 8-K · filed 2014-05-27 | $899.40K 10-Q · filed 2015-05-15 | $2.46M 8-K · filed 2014-05-27 | ||||||||
| 2014-02-28 | -$3.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-15 | -$12.66K 10-Q · filed 2014-04-15 | $2.63K 10-Q · filed 2014-04-15 | ||||||||
| 2013-12-31 | -$428.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13 | $1.96M 10-Q · filed 2015-02-13 | $1.75M 10-K · filed 2015-09-11 | $3.52M 8-K · filed 2014-05-27 | |||||||
| 2013-11-30 | -$9.12K 10-Q · filed 2014-01-13 | $6.17K 10-Q · filed 2014-01-13 | |||||||||
| 2013-09-30 | $2.39M 10-Q · filed 2014-11-07 | ||||||||||
| 2013-08-31 | $14.63K derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | $7.79K derived: sum of 2 quarters · filed 2013-12-16 | $6.34K 10-K · filed 2013-12-16 | $15.29K 10-K · filed 2013-12-16 | |||||||
| 2013-05-31 | -$6.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-12 | -$8.29K 10-Q · filed 2013-07-12 | $664.00 10-Q · filed 2013-07-12 | ||||||||
| 2013-03-31 | -$399.88K 8-K · filed 2014-05-27 | ||||||||||
| 2013-02-28 | -$2.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-15 | -$1.45K 10-Q · filed 2014-04-15 | -$4.79K derived: sum of 3 quarters · filed 2014-04-15 | $2.73K derived: sum of 4 quarters · filed 2014-04-15 | $7.50K 10-Q · filed 2013-05-03 | ||||||
| 2012-12-31 | $1.75M 10-KT · filed 2014-09-09 | ||||||||||
| 2012-11-30 | $1.50K 10-Q · filed 2014-01-13 | -$1.85K derived: sum of 2 quarters · filed 2014-01-13 | $5.67K derived: sum of 3 quarters · filed 2014-01-13 | ||||||||
| 2012-08-31 | -$3.34K derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | $4.17K derived: sum of 2 quarters · filed 2013-12-16 | $5.93K 10-K · filed 2013-12-16 | ||||||||
| 2012-05-31 | $7.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-12 | $9.28K 10-Q · filed 2013-07-12 | |||||||||
| 2012-02-29 | $1.76K 10-Q · filed 2013-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |